We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+3.58%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+221.81%
AUM
$69.4B
AUM Growth
+$3.54B
Cap. Flow
+$1.44B
Cap. Flow %
2.08%
Top 10 Hldgs %
21.44%
Holding
3,843
New
225
Increased
1,690
Reduced
1,576
Closed
217

Sector Composition

Rank Sector Weight
1 Technology 10.52%
2 Financials 9.29%
3 Healthcare 8.12%
4 Industrials 6.67%
5 Consumer Discretionary 5.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QQQ icon
51
Invesco QQQ Trust
QQQ
$480B
$232M 0.33%
1,240,361
+3,427
+0.3% +$631K
MA icon
52
Mastercard
MA
$500B
$226M 0.33%
854,211
+8,486
+1% +$2.12M
ISTB icon
53
iShares Core 1-5 Year USD Bond ETF
ISTB
$5.13B
$225M 0.32%
4,462,229
+185,491
+4% +$9.26M
BAC icon
54
Bank of America
BAC
$442B
$220M 0.32%
7,583,999
+300,431
+4% +$8.66M
KMB icon
55
Kimberly-Clark
KMB
$37.3B
$210M 0.3%
1,575,399
+11,565
+0.7% +$1.49M
BA icon
56
Boeing
BA
$190B
$210M 0.3%
576,660
-9,252
-2% -$3.37M
MDY icon
57
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27B
$206M 0.3%
580,013
-16,618
-3% -$5.81M
BP icon
58
BP
BP
$106B
$203M 0.29%
4,944,346
+607,357
+14% +$25.5M
ABBV icon
59
AbbVie
ABBV
$435B
$195M 0.28%
2,680,033
-1,703,375
-39% -$134M
HON icon
60
Honeywell
HON
$78.6B
$195M 0.28%
1,182,153
+17,779
+2% +$2.83M
CRM icon
61
Salesforce
CRM
$158B
$189M 0.27%
1,243,626
+16,010
+1% +$2.51M
FLRN icon
62
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
$3.09B
$185M 0.27%
6,033,353
+357,291
+6% +$11M
CVS icon
63
CVS Health
CVS
$126B
$185M 0.27%
3,402,213
+560,358
+20% +$30.2M
PM icon
64
Philip Morris
PM
$294B
$185M 0.27%
2,352,796
-74,552
-3% -$6.16M
VYM icon
65
Vanguard High Dividend Yield ETF
VYM
$82.5B
$184M 0.26%
2,103,328
-20,111
-0.9% -$1.74M
D icon
66
Dominion Energy
D
$60B
$183M 0.26%
2,366,653
+177,279
+8% +$13.5M
LMT icon
67
Lockheed Martin
LMT
$133B
$183M 0.26%
502,588
+27,343
+6% +$9.15M
MCHP icon
68
Microchip Technology
MCHP
$42.2B
$182M 0.26%
4,206,270
+284,994
+7% +$12.7M
IWM icon
69
iShares Russell 2000 ETF
IWM
$82.5B
$181M 0.26%
1,165,780
+72,744
+7% +$11.2M
MO icon
70
Altria Group
MO
$114B
$173M 0.25%
3,644,583
-72,022
-2% -$3.77M
INTC icon
71
Intel
INTC
$510B
$173M 0.25%
3,604,767
-77,224
-2% -$3.83M
CCL icon
72
Carnival Corporation Ltd
CCL
$40.6B
$168M 0.24%
3,609,915
+269,601
+8% +$14.1M
QCOM icon
73
Qualcomm
QCOM
$165B
$168M 0.24%
2,205,417
-20,492
-0.9% -$1.5M
SPIB icon
74
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
$11.5B
$168M 0.24%
4,802,736
+142,930
+3% +$4.9M
RSP icon
75
Invesco S&P 500 Equal Weight ETF
RSP
$99.3B
$168M 0.24%
1,554,496
+76,848
+5% +$8.14M

Similar funds

Raymond James & Associates's Q2 2019 Portfolio in Review

As of Q2 2019, Raymond James & Associates held 3,843 positions worth $69.4B, up 5.4% from $65.8B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Raymond James & Associates's Q2 2019 filing shows 225 new, 1,690 increased, 1,576 reduced and 217 closed positions. Its largest new stake was Dow Inc: 851,378 shares worth $42M. The largest sale was AbbVie, an estimated $134M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q2 2019 buy was Dow Inc: 851,378 shares worth $42M.
  • Raymond James & Associates added most to Medtronic in Q2 2019, an estimated $157M increase.
  • Raymond James & Associates's biggest Q2 2019 reduction was AbbVie, cutting an estimated $134M.
  • Raymond James & Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $5.43M.
  • Raymond James & Associates's ten largest holdings make up 21% of its $69.4B portfolio in Q2 2019.
  • Raymond James & Associates opened 225 new positions and closed 217 in Q2 2019.
  • Raymond James & Associates's portfolio value rose 5.4% quarter-over-quarter to $69.4B.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.